Enliven Therapeutics Inc (ELVN) concluded trading on Wednesday at a closing price of $21.57, with 0.42 million shares of worth about $9.14 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -6.83% during that period and on June 18, 2025 the price saw a loss of about -1.06%. Currently the company’s common shares owned by public are about 49.04M shares, out of which, 32.23M shares are available for trading.
Stock saw a price change of 10.02% in past 5 days and over the past one month there was a price change of 28.01%. Year-to-date (YTD), ELVN shares are showing a performance of -4.13% which decreased to -0.60% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $13.30 but also hit the highest price of $30.03 during that period. The average intraday trading volume for Enliven Therapeutics Inc shares is 420.70K. The stock is currently trading 9.84% above its 20-day simple moving average (SMA20), while that difference is up 15.73% for SMA50 and it goes to -3.23% lower than SMA200.
Enliven Therapeutics Inc (NASDAQ: ELVN) currently have 49.04M outstanding shares and institutions hold larger chunk of about 73.72% of that.
The stock has a current market capitalization of $1.24B and its 3Y-monthly beta is at 0.80. It has posted earnings per share of -$1.93 in the same period. It has Quick Ratio of 21.06 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ELVN, volatility over the week remained 7.25% while standing at 6.00% over the month.
Stock’s fiscal year EPS is expected to drop by -17.51% while it is estimated to decrease by -18.14% in next year. EPS is likely to shrink at an annualized rate of -24.58% for next 5-years, compared to annual growth of 19.02% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on June 16, 2025 offering a Buy rating for the stock and assigned a target price of $37 to it. Coverage by BTIG Research stated Enliven Therapeutics Inc (ELVN) stock as a Buy in their note to investors on December 13, 2024, suggesting a price target of $42 for the stock. On September 09, 2024, H.C. Wainwright Initiated their recommendations, while on June 11, 2024, Robert W. Baird Initiated their ratings for the stock with a price target of $32. Stock get a Buy rating from Mizuho on April 09, 2024.
